台万一

职称/职务：特聘研究员

通讯地址：湖北省武汉市武昌区东湖路185号9778818威尼斯

办公地址：9778818威尼斯医学部8号楼905室

办公电话： 

学习简历：

2000.09 - 2004.07 中国药科大学，中药药剂学学士

2004.09 - 2007.07 中国科学院上海药物研究所，药物化学硕士

2007.08 - 2012.08 美国密苏里大学堪萨斯城分校，药剂学博士

工作简历：

2012.09 - 2013.11 美国北卡罗来纳大学教堂山分校生物医学工程系，博士后

2013.12 - 2018.12 美国华盛顿大学生物工程系，博士后

2019.02 -    现在    9778818威尼斯，特聘研究员

研究领域

药剂学、抗体工程、生物材料、生物医学分析

研究兴趣与方向

● 生物大分子药物的结构设计和递药系统研究

以优化生物大分子药物的递送效率为目的，利用生物偶联、蛋白重组、定向突变、计算机辅助设计等手段，对抗体、核酸、蛋白类生物药物进行功能改造和结构优化，研究方向侧重于抗体-药物偶联技术、双功能杂交抗体设计、小干扰RNA结构修饰等生物技术。同时，针对生物大分子的特点，设计新型载药系统，探索大分子药物递送的新机制和新途径。

● 基因检测与分析技术

侧重于荧光原位杂交技术（FISH），设计新一类核酸荧光探针（FISH Probe），用于单细胞基因分析以及临床肿瘤学诊断。

● 药用生物材料的合成，靶向前药设计，以及药物制剂配方研究

设计合成医用高分子材料用于载药，药物偶联以及组织工程，同时兼顾开发一些多肽类靶向前药。课题组也涉及缓控释制剂、经皮给药系统等新剂型的配方研究。

代表性论文：

1.Wanyi Tai*. Current aspects of siRNA bioconjugate for in vitro and in vivo delivery. Molecules 2019, 24(12), 2211

2.Wanyi Tai*. Chemical Modulation of siRNA lipophilicity for efficient delivery. Journal of Controlled Release 2019, 307, 98-  107.

3.Wanyi Tai, Xiaohu Gao*. Silencing ribonucleoprotein: a biomimetic platform for targeted siRNA delivery. Advanced Functional Materials 2019, 29, 1902221

4.Wanyi Tai, Xiaohu Gao*. Synthetic polymer tag for intracellular delivery of siRNA. Advanced Biosystems 2018, 2. 1800075

5.Wanyi Tai, Junwei Li, Eva Corey, Xiaohu Gao*. A ribonucleoprotein octamer for targeted siRNA delivery. Nature Biomedical Engineering 2018, 2(5), 326-337

6.Wanyi Tai, Xiaohu Gao*. Noncovalent tagging of siRNA with steroids for transmembrane delivery. Biomaterials 2018, 178. 720-727.

7.Wanyi Tai, Xiaohu Gao*. Functional peptides for siRNA delivery Advanced Drug Delivery Reviews 2017, 110–111, 157–168.

8.Wanyi Tai, Ran Mo, Jin Di, Vinayak Subramanian, Xiao Gu, Zhen Gu*. Bio-inspired nanovesicles for glucose-responsive release of insulin. Biomacromolecules 2014, 15(10), 3495-3502.

9.Wanyi Tai#, Ran Mo#, Yue Lu, Tianyue Jiang, Zhen Gu*. Folding graft copolymer with pendant drug segment for co-delivery of anticancer drugs. Biomaterials 2014, 35(25), 7194-7203.

10.Wanyi Tai, Zhijin Chen, Ashutosh Barve, Zhonghua Peng, Kun Cheng*. A novel rapamycin-polymer conjugate based on a new poly(ethylene glycol) multiblock copolymer. Pharmaceutical Research 2014, 31(3), 706-719

11.Wanyi Tai, Zhijin Chen, Kun Cheng*. Expression profile and functional activity of peptide transporters in prostate cancer cells. Molecular Pharmaceutics 2013, 10(2), 477-487

12.Wanyi Tai, Ravi S. Shukla, Bin Qin, Benyi Li, Kun Cheng*. Development of a peptide-drug conjugate for prostate cancer therapy. Molecular Pharmaceutics 2011, 8(3), 901-912

13.Wan-Yi Tai#, Run-Tao Zhang#, Yi-Ming Ma, Min Gu, Gang Liu, Jia Li, Fa-Jun Nan*. Design, synthesis, and biological evaluation of ring‐opened bengamide analogues. ChemMedChem 2011, 6(9), 1555-1558.

14.Wanyi Tai, Rubi Mahato, Kun Cheng*. The role of HER2 in cancer therapy and targeted drug delivery. Journal of Controlled Release 2010, 146(3), 264-275

15.Wanyi Tai, Bin Qin, Kun Cheng*. Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER-2 and VEGF. Molecular Pharmaceutics 2010, 7(2), 543-556

16.Gang Liu#, Yi-Ming Ma#, Wan-Yi Tai#, Chuan-Ming Xie, Yu-Lin Li, Jia Li and Fa-Jun  Nan*. 2008, Design, synthesis, and biological evaluation of caprolactam-modified bengamide analogues. ChemMedChem 2008, 3(1), 74–78.

发表著作

1.Wanyi Tai, Zhen Gu*. Chapter 16 “Methods of folding a graft copolymer with dual anticancer drug and related applications” In Peter Grunwald edits “Biocatalysis & Nanotechnology” (2017), Pan Stanford Publishing Pte. Ltd.

2.Wanyi Tai, Kun Cheng*. Chapter 17 “Advanced drug delivery in cancer therapy” In Mitra AK, Lee C. Cheng K. edits “Advanced drug delivery” (2013), Wiley-Blackwell, John Wiley & Sons, Inc.

欢迎相关专业博士后、研究生、本科生加入本课题组。